A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.
Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid
Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lympho
